Search details
1.
Association between treatment-emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study.
Cancer
; 130(8): 1281-1291, 2024 Apr 15.
Article
in English
| MEDLINE | ID: mdl-38261521
2.
Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial.
Lancet
; 401(10372): 195-203, 2023 01 21.
Article
in English
| MEDLINE | ID: mdl-36681415
3.
Early Tumor Shrinkage and Depth of Response as Predictors of Survival for Advanced Biliary Tract Cancer: An Exploratory Analysis of JCOG1113.
Oncologist
; 29(1): e97-e107, 2024 Jan 05.
Article
in English
| MEDLINE | ID: mdl-37531645
4.
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study).
Invest New Drugs
; 2024 Jun 06.
Article
in English
| MEDLINE | ID: mdl-38842657
5.
Treatment outcomes of gemcitabine plus nab-paclitaxel in pancreatic cancer patients with malignant ascites.
Pancreatology
; 2024 Apr 04.
Article
in English
| MEDLINE | ID: mdl-38599956
6.
Phase II trial of niraparib for BRCA-mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B.
Future Oncol
; 2024 Apr 17.
Article
in English
| MEDLINE | ID: mdl-38629456
7.
Multicenter validation study of a treatment selection MAP for pancreatic neuroendocrine tumors.
Jpn J Clin Oncol
; 2024 Apr 27.
Article
in English
| MEDLINE | ID: mdl-38677983
8.
Current status of the cost burden of first-line systemic treatment for patients with advanced hepatocellular carcinoma in Japan, 2021-22.
Jpn J Clin Oncol
; 2024 Jun 07.
Article
in English
| MEDLINE | ID: mdl-38843879
9.
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 24(12): 1399-1410, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-38039993
10.
Fibroblast inhibition by tocilizumab enabled gemcitabine/nab-paclitaxel rechallenge for pancreatic cancer.
Cancer Sci
; 114(10): 4006-4019, 2023 Oct.
Article
in English
| MEDLINE | ID: mdl-37605479
11.
Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer.
Br J Cancer
; 128(8): 1603-1608, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36782009
12.
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
N Engl J Med
; 382(20): 1894-1905, 2020 05 14.
Article
in English
| MEDLINE | ID: mdl-32402160
13.
A Multicenter Survey on Eligibility for a Randomized Phase III Trial of Adjuvant Chemotherapy for Resected Biliary Tract Cancer (JCOG1202, ASCOT).
Ann Surg Oncol
; 30(12): 7331-7337, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37450093
14.
Optimal first-line treatment strategies of systemic therapy for unresectable gastrointestinal neuroendocrine tumors based on the opinions of Japanese experts.
Invest New Drugs
; 41(6): 777-786, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-37856005
15.
Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: Final results of a multicenter phase II study.
Hepatol Res
; 53(5): 409-416, 2023 May.
Article
in English
| MEDLINE | ID: mdl-36601972
16.
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines).
Hepatol Res
; 53(5): 383-390, 2023 May.
Article
in English
| MEDLINE | ID: mdl-36826411
17.
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer.
Future Oncol
; 19(34): 2277-2289, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37746835
18.
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Jpn J Clin Oncol
; 53(2): 130-137, 2023 Jan 28.
Article
in English
| MEDLINE | ID: mdl-36412114
19.
Comprehensive review of undifferentiated carcinoma of the pancreas: from epidemiology to treatment.
Jpn J Clin Oncol
; 53(9): 764-773, 2023 Aug 30.
Article
in English
| MEDLINE | ID: mdl-37325968
20.
Effect of systemic inflammatory response on induction chemotherapy followed by chemoradiotherapy for locally advanced pancreatic cancer: an exploratory subgroup analysis on systemic inflammatory response in JCOG1106.
Jpn J Clin Oncol
; 53(8): 704-713, 2023 Jul 31.
Article
in English
| MEDLINE | ID: mdl-37248668